{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:33:54Z","timestamp":1782452034288,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.prp.2019.152703","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:43:11Z","timestamp":1572003791000},"page":"152703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas"],"prefix":"10.1016","volume":"216","author":[{"given":"Jingrong","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2019.152703_bib0005","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.prp.2019.152703_bib0010","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.prp.2019.152703_bib0015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.beha.2018.07.010","article-title":"Peripheral T-cell lymphoma - are we making progress?","volume":"31","author":"Khan","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.prp.2019.152703_bib0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.it.2004.04.011","article-title":"The immunobiology of the TLR9 subfamily","volume":"25","author":"Wagner","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.prp.2019.152703_bib0025","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/0008-5472.CAN-14-1151","article-title":"TLR9 is critical for glioma stem cell maintenance and targeting","volume":"74","author":"Herrmann","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2019.152703_bib0030","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3892\/ol.2013.1204","article-title":"Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer","volume":"5","author":"Vaisanen","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2019.152703_bib0035","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3892\/or.2014.3095","article-title":"Functional expression of TLR9 in esophageal cancer","volume":"31","author":"Zhang","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2019.152703_bib0040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00428-017-2087-1","article-title":"High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients","volume":"470","author":"Leppanen","year":"2017","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2019.152703_bib0045","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.1002726","article-title":"Tumor infiltrating CD8(+) T lymphocyte count is independent of tumor TLR9 status in treatment naive triple negative breast cancer and renal cell carcinoma","volume":"4","author":"Mella","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.prp.2019.152703_bib0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.prp.2019.152703_bib0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.20892\/j.issn.2095-3941.2018.0047","article-title":"The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis","volume":"15","author":"Zhao","year":"2018","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.prp.2019.152703_bib0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology."},{"key":"10.1016\/j.prp.2019.152703_bib0065","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2019.152703_bib0070","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of Nivolumab in previously treated advanced non-small-Cell lung Cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2019.152703_bib0075","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/2326-6066.CIR-13-0224","article-title":"Programmed cell death ligand 1 expression in osteosarcoma","volume":"2","author":"Shen","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2019.152703_bib0080","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/his.13475","article-title":"Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells","volume":"72","author":"Sakakibara","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2019.152703_bib0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000437294","article-title":"T-cell lymphomas presenting as Colon ulcers and eosinophilia","volume":"9","author":"Wu","year":"2015","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.prp.2019.152703_bib0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1743-422X-8-213","article-title":"Human-derived IgG level as an indicator for EBV-associated lymphoma model in Hu-PBL\/SCID chimeras","volume":"8","author":"Tang","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.prp.2019.152703_bib0095","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.prp.2019.152703_bib0100","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00432-019-02874-7","article-title":"Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy","volume":"145","author":"Chen","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.prp.2019.152703_bib0105","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2019.152703_bib0110","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2019.152703_bib0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.wneu.2016.10.015","article-title":"Tumor location and survival outcomes in adult patients with supratentorial glioblastoma by levels of toll-like receptor 9 expression","volume":"97","author":"Mu","year":"2017","journal-title":"World Neurosurg."},{"key":"10.1016\/j.prp.2019.152703_bib0120","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1038\/onc.2013.302","article-title":"The Yin and Yang of Toll-like receptors in cancer","volume":"33","author":"Pradere","year":"2014","journal-title":"Oncogene."},{"key":"10.1016\/j.prp.2019.152703_bib0125","first-page":"996","article-title":"Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer","volume":"17","author":"Wu","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.prp.2019.152703_bib0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcancer.2016.07.001","article-title":"Toll-like receptors signaling: a complex network for NF-kappaB activation in B-cell lymphoid malignancies","volume":"39","author":"Ntoufa","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.prp.2019.152703_bib0135","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting t cell Co-receptors for Cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.prp.2019.152703_bib0140","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.4049\/jimmunol.169.7.3581","article-title":"B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis","volume":"169","author":"Mazanet","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.prp.2019.152703_bib0145","first-page":"1193","article-title":"Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy","volume":"53","author":"Wang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2019.152703_bib0150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.prp.2019.152703_bib0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019001043","article-title":"A novel model of controlling PD-L1 expression in ALK(+) anaplastic large cell lymphoma revealed by CRISPR screening","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.prp.2019.152703_bib0160","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/labinvest.2017.54","article-title":"EMMPRIN (CD147) is induced by C\/EBPbeta and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma","volume":"97","author":"Schmidt","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.prp.2019.152703_bib0165","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prp.2019.152703_bib0170","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00248-19","article-title":"High-throughput sequence analysis of peripheral T-Cell lymphomas indicates subtype-specific viral gene expression patterns and immune cell microenvironments","volume":"4","author":"Nakhoul","year":"2019","journal-title":"mSphere."},{"key":"10.1016\/j.prp.2019.152703_bib0175","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3109\/10428194.2013.861068","article-title":"Epstein-Barr virus present in T cells or B cells shows differential effects on hemophagocytic symptoms associated with outcome in T-cell lymphomas","volume":"55","author":"Chen","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.prp.2019.152703_bib0180","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","article-title":"Groupe d\u2019Etude des Lymphomes de, Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.prp.2019.152703_bib0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2018-02-833806","article-title":"Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?","volume":"132","author":"Carbone","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.prp.2019.152703_bib0190","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/bloodadvances.2018018754","article-title":"Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS","volume":"2","author":"Sugio","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.prp.2019.152703_bib0195","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/16078454.2019.1590965","article-title":"Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis","volume":"24","author":"Shen","year":"2019","journal-title":"Hematology."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033819316024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033819316024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:41:10Z","timestamp":1759732870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033819316024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0344033819316024"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2019.152703","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2019.152703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152703"}}